Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating TransMedics Group, Ltd. for potential violations of securities laws

Globe Newswire 22-Jan-2025 8:03 AM

PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION

NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of TransMedics Group, Ltd. (NASDAQ:TMDX) ("TransMedics" or the "Company").

The investigation concerns whether TransMedics and certain of its officers and/or directors have engaged in securities fraud.

PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.

On January 10, 2025, Scorpion Capital issued a report about the Company alleging fraud, organ trafficking, and off-label device misuse. It stated that in "20 years of shorting, TransMedics is the most extreme and grotesque healthcare fraud we have encountered, not only for its scale, but because it is predicated on the exploitation of the most vulnerable patients - the terminally ill, desperate for an organ. The ‘lucky' patients who receive a diseased, damaged organ rejected by reputable surgeons and centers [. . .] are oblivious to the cesspool of perverse, secret incentives that steered the organ their way. [Corruption pervades] every aspect of the business model." Following this news, TransMedics stock dropped $3.74 per share, or 5.15%, to close at $68.81 on January 10, 2025.

On January 13, 2025, TransMedics stock dropped another $4.76 per share, or 6.9%, to close at $64.05.

Wolf Haldenstein has experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas, and offices in New York, Chicago, Nashville and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly lauded by the courts, which have appointed it to major positions in complex securities, multi-district and consolidated litigation.

If you wish to discuss this investigation or have any questions regarding your rights and interests, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735 or via e-mail at classmember@whafh.com.

Contact:

Wolf Haldenstein Adler Freeman & Herz LLP
Gregory Stone, Director of Case and Financial Analysis
Email: gstone@whafh.com or classmember@whafh.com
Tel: (800) 575-0735 or (212) 545-4774

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.